Biocardia Company Insiders
| BCDA Stock | USD 1.23 0.04 3.15% |
Biocardia's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Biocardia suggests that vertually all insiders are extremely bullish. Biocardia employs about 17 people. The company is managed by 7 executives with a total tenure of roughly 18 years, averaging almost 2.0 years of service per executive, having 2.43 employees per reported executive.
| Peter Altman CEO President CEO, Principal Executive Officer, Director |
| David McClung President Principal Financial and Accounting Officer, Vice President - Finance |
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-09-19 | Andrew Scott Blank | Acquired 288000 @ 1.25 | View | ||
| 2025-08-22 | Peter Altman | Acquired 700 @ 1.83 | View | ||
| 2025-08-13 | Peter Altman | Acquired 100 @ 1.83 | View | ||
| 2025-08-12 | Peter Altman | Acquired 400 @ 1.75 | View | ||
| 2025-08-11 | Peter Altman | Acquired 1700 @ 1.76 | View | ||
| 2025-06-30 | Simon H Stertzer | Acquired 72289 @ 2.08 | View | ||
| 2025-05-30 | Peter Altman | Acquired 100 @ 2.21 | View | ||
| 2025-05-22 | Peter Altman | Acquired 700 @ 1.89 | View | ||
| 2025-05-20 | Peter Altman | Acquired 1600 @ 2.08 | View | ||
| 2025-05-16 | Peter Altman | Acquired 300 @ 2.43 | View | ||
| 2025-05-14 | Peter Altman | Acquired 100 @ 2.99 | View | ||
| 2025-04-23 | Peter Altman | Acquired 26246 @ 1.91 | View | ||
| 2025-04-15 | Peter Altman | Acquired 100 @ 2.14 | View | ||
| 2025-04-10 | Peter Altman | Acquired 300 @ 1.99 | View |
Monitoring Biocardia's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Biocardia | Build AI portfolio with Biocardia Stock |
Biocardia Management Team Effectiveness
The company has return on total asset (ROA) of (0.8645) % which means that it has lost $0.8645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1747) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.03. The current year's Return On Capital Employed is expected to grow to -5.42. At present, Biocardia's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 235.3 K, whereas Total Assets are forecasted to decline to about 3.5 M.The current year's Common Stock Shares Outstanding is expected to grow to about 2.9 M, whereas Net Loss is forecasted to decline to (11.3 M).
Biocardia Workforce Comparison
Biocardia is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 149. Biocardia retains roughly 17.0 in number of employees claiming about 11% of equities under Health Care industry.
Biocardia Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biocardia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Peter Altman over a week ago Acquisition by Peter Altman of 900 shares of Biocardia at 1.3 subject to Rule 16b-3 | ||
Slosman Marvin over two weeks ago Acquisition by Slosman Marvin of 12000 shares of Biocardia at 1.37 subject to Rule 16b-3 | ||
Slosman Marvin over three weeks ago Insider Trading | ||
Peter Altman over a month ago Acquisition by Peter Altman of 41666 shares of Biocardia at 3.0 subject to Rule 16b-3 | ||
Peter Altman over two months ago Disposition of 21680 shares by Peter Altman of Biocardia at 2.65 subject to Rule 16b-3 | ||
Peter Altman over three months ago Acquisition by Peter Altman of 700 shares of Biocardia at 1.83 subject to Rule 16b-3 | ||
Blank Andrew Scott over six months ago Acquisition by Blank Andrew Scott of 72289 shares of Biocardia at 1.95 subject to Rule 16b-3 | ||
Peter Altman over six months ago Acquisition by Peter Altman of 100 shares of Biocardia at 2.21 subject to Rule 16b-3 |
Biocardia Notable Stakeholders
A Biocardia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biocardia often face trade-offs trying to please all of them. Biocardia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biocardia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Altman | President CEO, Principal Executive Officer, Director | Profile | |
| David McClung | Principal Financial and Accounting Officer, Vice President - Finance | Profile | |
| Edward Gillis | Senior Devices | Profile | |
| Ian McNiece | Chief Officer | Profile | |
| Sujith Shetty | Chief Regulatory | Profile | |
| Sujith MBBS | Chief Regulatory | Profile | |
| Miranda Benvenuti | Investor Executive | Profile |
About Biocardia Management Performance
The success or failure of an entity such as Biocardia often depends on how effective the management is. Biocardia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biocardia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biocardia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.13) | (2.03) | |
| Return On Capital Employed | (5.70) | (5.42) | |
| Return On Assets | (2.13) | (2.03) | |
| Return On Equity | (9.49) | (9.02) |
Please note, the presentation of Biocardia's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.
Biocardia Workforce Analysis
Traditionally, organizations such as Biocardia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biocardia within its industry.Biocardia Manpower Efficiency
Return on Biocardia Manpower
| Revenue Per Employee | 3.4K | |
| Revenue Per Executive | 8.3K | |
| Net Loss Per Employee | 467.4K | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 17.7K | |
| Working Capital Per Executive | 43K |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |